• Profile
Close

Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience

British Journal of Ophthalmology May 19, 2019

Petkovsek DS, et al. - Via this retrospective chart analysis, researchers assessed 3-year clinical outcomes of patients who received eplerenone for the treatment of chronic central serous chorioretinopathy (CSCR). At eplerenone initiation, baseline best-corrected visual acuity, as well as anatomical measurements associated with the degree of subretinal fluid (SRF), were obtained. At the closest date to 12, 24 and 36 months, follow-up data were gathered. They collected data at 1-year, 2-year, and 3-year follow-up visits, for 100 eyes of 83 patients, 49 eyes, and for 33 eyes, respectively. The observed rate of complete SRF resolution was 31%, 28% and 33%, respectively. In patients treated with eplerenone for chronic CSCR, the occurrence of anatomical improvement was evident primarily within the first year of treatment.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay